Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 8:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: dalteparin Clear all
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Not applicable Interventional

LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin

NCT00321009
View directory record Official record
Conditions
Coronary Artery Disease, Acute Myocardial Infarction
Interventions
Enoxaparin
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
6
States / cities
Denver, Colorado • Royal Oak, Michigan • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 2, 2006 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement

NCT00152971
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Thromboembolism
Interventions
Dabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion, Dabigatran Dose 2 - day 1, Enoxaparin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
59
States / cities
Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 4, 2014 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 3 Interventional

Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

NCT00329628
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (BAY59-7939), Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Sep 16, 2026, 8:40 AM EDT
Completed No phase listed Observational

Validation of Rivaroxaban Assay for US Registration

NCT02333929
View directory record Official record
Conditions
Patients Receiving Rivaroxaban Treatment
Interventions
STA- Rivaroxaban Calibrator&Control
Device
Lead sponsor
Diagnostica Stago
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Sep 16, 2026, 8:40 AM EDT
Not listed Phase 3 Interventional

Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose

NCT02486666
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis

NCT02070237
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Pregnancy, Complications; Cesarean Section, Venous Thromboembolism, Postpartum Deep Phlebothrombosis, Pulmonary Embolism
Interventions
Enoxaparin
Drug
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2015 · Synced Sep 16, 2026, 8:40 AM EDT
Terminated Phase 3 Interventional Results available

Clot Dissolving Treatment for Blood Clots in the Lungs

NCT00680628
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Tenecteplase + Enoxaparin, 0.9% Saline + Enoxaparin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00643201
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 3 Interventional

SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism

NCT00062803
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
SR34006, (LMW)heparin, Warfarin VKA, Acenocoumarol VKA
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
54
States / cities
Loma Linda, California • San Diego, California • Aurora, Colorado + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 16, 2026, 8:40 AM EDT
Active, not recruiting Phase 4 Interventional

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

NCT04790370
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Anticoagulation with heparin, EkoSonicTM Endovascular System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Newark, Delaware + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 2 Interventional

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome

NCT00932100
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
REG1, Heparin
Drug
Lead sponsor
Regado Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
26
States / cities
Huntsville, Alabama • Sacramento, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Not applicable Interventional Results available

Once Weekly Subcutaneous Ports for the Administration of Anticoagulants

NCT00774748
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Insuflon
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

NCT00679588
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin Sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 16, 2026, 8:40 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy

NCT00721591
View directory record Official record
Conditions
Recurrent Pregnancy Loss, Fetal Demise, Abortion, Habitual, Antiphospholipid Antibodies, Inherited Thrombophilia
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 3 Interventional

Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs

NCT00311090
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Idrabiotaparinux sodium, Idraparinux sodium, Avidin, Placebo (for Avidin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 16, 2026, 8:40 AM EDT
Completed No phase listed Observational

Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)

NCT00933738
View directory record Official record
Conditions
Coagulation
Interventions
Not listed
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Loma Linda, California • Aurora, Colorado • Detroit, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 4 Interventional Results available

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

NCT00966277
View directory record Official record
Conditions
Pancreatic Cancer, Venous Thromboembolism
Interventions
Dalteparin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Not applicable Interventional Results available

Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism

NCT00413374
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 16, 2026, 8:40 AM EDT
Recruiting Phase 2 Interventional

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

NCT06004674
View directory record Official record
Conditions
Adverse Pregnancy Outcome
Interventions
Lovenox 40mg
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 16, 2026, 8:40 AM EDT
Completed No phase listed Observational Results available

A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer

NCT05643885
View directory record Official record
Conditions
Thromboembolism
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
7,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 16, 2026, 8:40 AM EDT
No Longer Available No phase listed Expanded access

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

NCT01049633
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

PREVENTion of Clot in Orthopaedic Trauma

NCT02984384
View directory record Official record
Conditions
Blood Clot, Trauma
Interventions
Acetylsalicylic acid, Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years and older
Enrollment
12,424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Tucson, Arizona • Miami, Florida • Indianapolis, Indiana + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 16, 2026, 8:40 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.

NCT00878826
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 16, 2026, 8:40 AM EDT